In this cross-sectional study, in patients with type 2 diabetes and stage 5 CKD or ESKD, use of GLP-1 receptor agonists was associated with better outcomes, including all-cause mortality and sepsis- and infection-related mortality, compared with use of DPP-4 inhibitors. Here, GLP1R is linked to type 2 diabetes mellitus.